A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

ClinicalTrials.gov ID: NCT01774851

Public ClinicalTrials.gov record NCT01774851. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 12:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone

Study identification

NCT ID: NCT01774851
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Merrimack Pharmaceuticals; Industry
Enrollment: 84 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2012
Primary completion: Jun 30, 2015
Completion: Nov 30, 2015
Last update posted: Jun 21, 2017

2013 – 2015

United States locations

U.S. sites: 21
U.S. states: 15
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35294	—
Not listed	Los Angeles	California	90089	—
Not listed	Los Angeles	California	90095	—
Not listed	Stanford	California	94305	—
Not listed	Denver	Colorado	80218	—
Not listed	Ocala	Florida	34471	—
Not listed	St. Petersburg	Florida	33705	—
Not listed	Urbana	Illinois	61801	—
Not listed	Boston	Massachusetts	02111	—
Not listed	Boston	Massachusetts	02114	—
Not listed	Rochester	Minnesota	55905	—
Not listed	St Louis	Missouri	63110	—
Not listed	Las Vegas	Nevada	89135	—
Not listed	Buffalo	New York	14263	—
Not listed	Durham	North Carolina	27710	—
Not listed	Cleveland	Ohio	44106	—
Not listed	Columbus	Ohio	43210	—
Not listed	Philadelphia	Pennsylvania	19111	—
Not listed	Pittsburgh	Pennsylvania	15232	—
Not listed	Nashville	Tennessee	37203	—
Not listed	Wenatchee	Washington	98801	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01774851, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 21, 2017 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01774851 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →